Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
1(100.0%)
1Total
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05367947Not ApplicableCompleted

In-phase Bilateral Exercises in People With Relapsing Remitting Multiple Sclerosis

Role: collaborator

NCT02890134Completed

Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases: Inception Cohort

Role: collaborator

NCT02890121Completed

Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases:

Role: collaborator

NCT02890147Completed

Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases: Case-control

Role: collaborator

All 4 trials loaded